[Drug-eluting stents: do they keep their promises?].
Nordmann
A
A
Institut für Klinische Epidemiologie, Universitätsspital Basel. nordmanna@uhbs.ch
D015906:Angioplasty, Balloon, Coronary; D003327:Coronary Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D016503:Drug Delivery Systems; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D015201:Meta-Analysis as Topic; D009026:Mortality / Q000639:trends; D009203:Myocardial Infarction / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control; D016017:Odds Ratio; D017239:Paclitaxel / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents / Q000009:adverse effects / Q000191:economics; D013997:Time Factors
D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus